Abstract
Ketamine acts mainly as a N-methyl-D-aspartate receptor (NMDAr) antagonist. Originally developed as a general anesthetic, it is now seldom employed as such in richer countries due to the relatively high risk of psychotomimetic adverse effects. Recently, low – dose regimens in the range of 0.25 – 0.5 mg/kg as an initial bolus followed by 50 – 500 μg/kg/h have been proposed as an adjuvant for postoperative analgesia and for the reduction of exogenous opioid – induced hyperalgesia. In this review, we examine the evidence for clinical usefulness of perioperative ketamine infusion and its role in the context of general and/or regional anesthesia.
Keywords: Ketamine, analgesia, perioperative care, pain, postoperative, analgesics, non-narcotic
Current Drug Targets
Title: Clinical Uses of Low – Dose Ketamine in Patients Undergoing Surgery
Volume: 10 Issue: 8
Author(s): M. Berti, M. Baciarello, R. Troglio and G. Fanelli
Affiliation:
Keywords: Ketamine, analgesia, perioperative care, pain, postoperative, analgesics, non-narcotic
Abstract: Ketamine acts mainly as a N-methyl-D-aspartate receptor (NMDAr) antagonist. Originally developed as a general anesthetic, it is now seldom employed as such in richer countries due to the relatively high risk of psychotomimetic adverse effects. Recently, low – dose regimens in the range of 0.25 – 0.5 mg/kg as an initial bolus followed by 50 – 500 μg/kg/h have been proposed as an adjuvant for postoperative analgesia and for the reduction of exogenous opioid – induced hyperalgesia. In this review, we examine the evidence for clinical usefulness of perioperative ketamine infusion and its role in the context of general and/or regional anesthesia.
Export Options
About this article
Cite this article as:
Berti M., Baciarello M., Troglio R. and Fanelli G., Clinical Uses of Low – Dose Ketamine in Patients Undergoing Surgery, Current Drug Targets 2009; 10 (8) . https://dx.doi.org/10.2174/138945009788982496
DOI https://dx.doi.org/10.2174/138945009788982496 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response and/or therapy ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Adrenergic and V1-ergic Agonists/Antagonists Affecting Recovery from Brain Trauma in the Lund Project Act on Astrocytes
Current Signal Transduction Therapy The Genetics of Small-Vessel Disease
Current Medicinal Chemistry Beta-blockers in Intensive Care Medicine: Potential Benefit in Acute Brain Injury and Acute Respiratory Distress Syndrome
Recent Patents on Cardiovascular Drug Discovery Longitudinal Association between White Matter Hyperintensities and White Matter Beta-Amyloid Deposition in Cognitively Unimpaired Elderly
Current Alzheimer Research Encapsulation of Imatinib in Targeted KIT-5 Nanoparticles for Reducing its Cardiotoxicity and Hepatotoxicity
Anti-Cancer Agents in Medicinal Chemistry Optimal Sedation for the Ventilation of Critically Ill Patients
Current Respiratory Medicine Reviews Substance Abuse and Movement Disorders
Current Drug Abuse Reviews Antiplatelet Treatment in Peripheral Arterial Disease: The Role of Novel Antiplatelet Agents
Current Pharmaceutical Design Challenges and Perspectives of Antiplatelet Therapy in Patients with Diabetes Mellitus and Coronary Artery Disease
Current Pharmaceutical Design The Potential for Substance P Antagonists as Anti-Cancer Agents in Brain Tumours
Recent Patents on CNS Drug Discovery (Discontinued) Adrenergic Drugs Blockers or Enhancers for Cognitive Decline ? What to Choose for Alzheimer’s Disease Patients?
CNS & Neurological Disorders - Drug Targets Which Drugs for the Control of Fever in Critical Patients
Current Drug Targets Intracerebral Hemorrhage and Diabetes Mellitus: Blood-Brain Barrier Disruption, Pathophysiology and Cognitive Impairments
CNS & Neurological Disorders - Drug Targets New Anti-Thrombotic Drugs for Stroke Prevention
Current Vascular Pharmacology Controlled Drug Delivery Using Microdevices
Current Pharmaceutical Biotechnology Transcranial Doppler Ultrasonography: Current Status
Current Medical Imaging Posterior Reversible Encephalopathy Syndrome with Atypical Presentation: A Pictorial Review on MR Imaging Features
Current Medical Imaging Conference Report (8th Annual Meeting of the Society for the Study of Neuroprotection and Neuroplasticity)
CNS & Neurological Disorders - Drug Targets Takotsubo Cardiomyopathy
Current Pharmaceutical Design Anti-Inflammatory Intervention for Acute Liver Failure: Recent Patents and Future Targets
Recent Patents on Biomarkers